Vor(US:VOR)2026-03-30 12:03Financial Performance - Vor Bio reported a net loss of $696.0 million for the year ended December 31, 2025, compared to a net loss of $116.9 million for the year ended December 31, 2024, representing an increase in losses of $579.1 million[438][454]. - Total operating expenses for 2025 were $371.6 million, a significant increase of $250.5 million from $121.2 million in 2024[454]. - Vor Bio's accumulated deficit reached $1,153.0 million as of December 31, 2025[438]. - Net cash used in operating activities was $142.7 million for the year ended December 31, 2025, reflecting a net loss of $696.0 million[475]. - Other income (expense), net decreased by $328.6 million for the year ended December 31, 2025, primarily due to a $334.4 million loss on the change in fair value of warrant liabilities[458]. Research and Development - Research and development expenses surged to $321.5 million in 2025, up from $93.3 million in 2024, primarily due to a $222.6 million expense for the telitacicept license acquisition[456]. - Vor Bio initiated a global Phase 3 clinical trial for telitacicept in Sjögren's disease, with first patient dosing in March 2026, aiming to recruit approximately 250 adults[436]. - Vor Bio's Phase 3 clinical trial for generalized myasthenia gravis (gMG) is currently recruiting patients globally, with topline data expected in the first half of 2027[434]. - The company expects to incur substantial additional costs associated with clinical trials and regulatory approvals, which may delay revenue generation[469][470]. Funding and Cash Position - As of December 31, 2025, Vor Bio had cash, cash equivalents, and marketable securities totaling $455.2 million, expected to fund operations into early 2029[439]. - Net cash provided by financing activities was $503.8 million for the year ended December 31, 2025, including $175.0 million from the June 2025 Private Placement and $107.7 million from the November 2025 Offering[479]. - The company raised approximately $1,019.1 million from equity securities sales as of December 31, 2025, to fund operations[459]. - The December 2025 Private Placement resulted in net proceeds of $149.9 million after issuing 13,876,032 shares at a price of $10.81 per share[465]. - The company sold 1,910,861 shares under the Stifel ATM Facility in 2025, generating net proceeds of $70.1 million at a weighted average price of $37.06 per share[461]. - The company anticipates needing substantial additional funding to support ongoing operations and growth strategies, with potential impacts from global economic conditions[472]. Corporate Structure and Compliance - The company has elected to use the extended transition period for complying with new or revised accounting standards, delaying adoption until they apply to private companies[489]. - As an emerging growth company, the company benefits from reduced disclosure requirements until the end of the fiscal year following the fifth anniversary of its IPO or until it no longer qualifies[490]. - The company may present only two years of audited consolidated financial statements, with reduced disclosure in the Management's Discussion and Analysis section[491]. - The company is classified as a smaller reporting company, allowing it to continue relying on exemptions from certain disclosure requirements after ceasing to be an emerging growth company[493]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[495]. Restructuring and Workforce - The company has incurred restructuring costs of $29.7 million related to its Restructuring Plan, which included a workforce reduction of 154 employees, approximately 99% of its then-current employee base[440][441].